Evidence map›Paper›PMID 33713196›Full record

ArticleMedical oncology (Northwood, London, England)2021

Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.

Yumina Muto, Shintaro Narita, Shingo Hatakeyama, Shinya Maita, Shuji Chiba, Kyohei Kubo, Yuu Aoyama, Ryuichi Ito, Yoshiko Takahashi, Shuhei Takahashi and 14 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 1 country.

Yumina MutoDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Shintaro NaritaDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. naritashintaro@gmail.com.ORCID http://orcid.org/0000-0003-2988-1860
Shingo HatakeyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Shinya MaitaDepartment of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
Shuji ChibaDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Kyohei KuboDepartment of Urology, Hiraka General Hospital, Yokote, Japan.
Yuu AoyamaDepartment of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
Ryuichi ItoDepartment of Urology, Yuri Kumiai General Hospital, Yurihonjo, Japan.
Yoshiko TakahashiDepartment of Urology, Omagari Kousei Medical Center, Akita, Japan.
Shuhei TakahashiDepartment of Urology, Akita Red Cross Hospital, Akita, Japan.
Kumiko NakamuraDepartment of Urology, Akita City Hospital, Akita, Japan.
Naoko HonmaDepartment of Urology, Akita Kousei Medical Center, Akita, Japan.
Hiromi SatoDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Atsushi KoizumiDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Ryoma IgarashiDepartment of Urology, Yokote Municipal Hospital, Akita, Japan.
Katsumi OkaneDepartment of Urology, Akita Kousei Medical Center, Akita, Japan.
Toshiya IshidaDepartment of Urology, Akita City Hospital, Akita, Japan.
Yohei HorikawaDepartment of Urology, Akita Red Cross Hospital, Akita, Japan.
Teruaki KumazawaDepartment of Urology, Omagari Kousei Medical Center, Akita, Japan.
Susumu AkihamaDepartment of Urology, Yuri Kumiai General Hospital, Yurihonjo, Japan.
Jiro ShimodaDepartment of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
Takehiro SuzukiDepartment of Urology, Hiraka General Hospital, Yokote, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Tomonori HabuchiDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Akita University · JPIwate Prefectural Central Hospital · JPAkita Industrial Technology Center · JPAkita Red Cross Hospital · JPAkita University Hospital · JPHiraka General Hospital · JPHirosaki University · JPYokosuka Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a risk-adapted upfront docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here, we reported an interim analysis of the study. The study enrolled 68 patients with newly diagnosed mHSPC between 2016 and 2018. According to the presence of visceral metastasis, an EOD score ≥ 3, or prostate-specific antigen (PSA) level at 3 months of ≥ 1 ng/mL, patients were divided into low- and high-risk groups. Patients were treated with androgen deprivation therapy (ADT) with or without bicalutamide; those in the high-risk group received upfront treatment involving six cycles of DOC (70 mg/m

Indexed as

AgedAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelHumansJapanMaleMiddle AgedProspective StudiesProstate-Specific AntigenProstatic NeoplasmsQuality of LifeTreatment OutcomeAndrogen AntagonistsDocetaxelProstate-Specific AntigenChemotherapyDocetaxelHormone naïveHormone sensitiveMetastaticProstate cancer

Identifiers

PMID33713196
OpenAlexW3135594221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.